# Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

> **NCT00069706** · PHASE2 · COMPLETED · sponsor: **Alcon Research** · enrollment: 118 (actual)

## Conditions studied

- Open-angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** AL-12182 0.003% Ophthalmic Solution
- **OTHER:** AL-12182 Ophthalmic Solution Vehicle
- **DRUG:** Latanoprost 0.005% Ophthalmic Solution
- **DRUG:** AL-12182 0.01% Ophthalmic Solution
- **DRUG:** AL-12182 0.03% Ophthalmic Solution

## Key facts

- **NCT ID:** NCT00069706
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2012-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00069706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00069706, "Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00069706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*